Ocugen said it will present its modifier gene therapy platform at key 2026 ophthalmology conferences, including EIS, EURETINA and the AAO Annual Meeting. The move underscores its push to advance genetic eye disease therapies, including OCU400.
published
Ocugen said it will present its modifier gene therapy platform at key 2026 ophthalmology conferences, including EIS, EURETINA and the AAO Annual Meeting. The move underscores its push to advance genetic eye disease therapies, including OCU400.
Latest documented BWB result
$TSLA · $SPY market result
Exit $TSLA PDS with a .60 profit per contract - was willing to hold if $SPY closed under the SMA 50 but not with a close above it
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.